Rizkiawan Diondra Eka, Evelyn Malinda, Tjandra Kevin Christian, Setiawan Budi
Faculty of Medicine, Diponegoro University, Semarang, Central Java, Indonesia.
Department of Internal Medicine, Diponegoro University, Semarang, Central Java, Indonesia.
Clin Ophthalmol. 2022 Aug 29;16:2851-2859. doi: 10.2147/OPTH.S372114. eCollection 2022.
Glaucoma is an optic neuropathy disease that causes cupping of the optic disc and decreased visual field. Glaucoma is still the second leading cause of blindness globally, with a worldwide prevalence of more than 76 million people in 2020. However, no therapy can cure glaucoma completely, especially when optic nerve damage has occurred. Available treatments only play a role in keeping the intraocular pressure stable This research aims to determine the potential use of modified stem cell therapy to treat intraocular damage in glaucoma cases. Literature research was conducted by involving seven online databases, namely Pubmed, ScienceDirect, Proquest, EBSCOhost, SAGE, Clinicalkey, and Scopus, published between 2010-2020 with the keywords stem cells; therapy; glaucoma; optic nerve. Six articles were selected, and out of the six articles, all writings were experimental research. The entire literature states that modified stem cell therapy has the potential as a therapeutic option in treating intraocular damage in patients with glaucoma. Based on the systematic literature review that has been carried out, it is known that stem cell therapy has the potential to be a therapeutic option in treating glaucoma cases. Much more research is needed to assess the effectiveness of modified stem cell therapy in managing intraocular damage due to glaucoma.
青光眼是一种导致视盘凹陷和视野缩小的视神经病变疾病。青光眼仍是全球第二大致盲原因，2020年全球患病率超过7600万人。然而，尚无疗法能完全治愈青光眼，尤其是在视神经已受损的情况下。现有治疗仅在维持眼压稳定方面发挥作用。本研究旨在确定改良干细胞疗法治疗青光眼病例眼内损伤的潜在用途。通过检索七个在线数据库进行文献研究，这些数据库分别是Pubmed、ScienceDirect、Proquest、EBSCOhost、SAGE、Clinicalkey和Scopus，检索2010 - 2020年间发表的文章，关键词为干细胞；疗法；青光眼；视神经。共筛选出六篇文章，且这六篇文章均为实验研究。所有文献均表明改良干细胞疗法有潜力成为治疗青光眼患者眼内损伤的一种治疗选择。基于已开展的系统文献综述可知，干细胞疗法有潜力成为治疗青光眼病例的一种治疗选择。需要更多研究来评估改良干细胞疗法治疗青光眼所致眼内损伤的有效性。
